Myriad's HRD Score Detects Loss of DNA Repair Function in Ovarian Cancer
Myriad Genetics (NASDAQ: MYGN) announced today that a study published in the British Journal of Cancer demonstrated the ability of the Company's Homologous Recombination Deficiency (HRD) Assay to detect loss of DNA repair in ovarian tumors. The study, entitled, "Patterns of Genomic Loss of Heterozygosity Predict Homologous Recombination Repair Defects in Epithelial Ovarian Cancer," confirmed, with highly statistically significant results, the relationship between Myriad's HRD score and tumors deficient in DNA repair.
"By measuring the HRD score in tumor samples we expect to be able to predict patient response to therapeutic agents that exploit deficiencies in DNA repair," said Jerry Lanchbury Ph.D., Chief Scientific Officer of Myriad Genetics Inc. "Through this best-in-class test we intend to provide patients and their healthcare providers with critical information regarding response to platinum drugs or PARP inhibitors across multiple cancers including breast, ovarian and other cancers."
Researchers at M.D. Anderson Cancer Center, University of California, San Francisco, University of Pittsburgh, University of British Colombia, Royal College of Surgeons in Ireland, and Myriad Genetics generated HRD scores in 639 ovarian tumor samples as well as 57 breast and pancreatic cancer cell lines. The data demonstrated that a high HRD score is highly correlated (p = 1.0 x 10^-48) with tumor deficiency in DNA repair.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.